A. de Boer

First name
A.
Last name
de Boer
der Zanden, W., de Vries, F., Lalmohamed, A., Driessen, J. H., de Boer, A., Rohde, G., et al. (2015). Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. PLoS One. http://doi.org/10.1371/journal.pone.0139367
View
Nielen, J. T., de Vries, F., Dagnelie, P. C., van den Bemt, B. J., Emans, P. J., Lalmohamed, A., et al. (2016). Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.12786
View
Warnier, M. J., Rutten, F. H., Souverein, P. C., de Boer, A., Hoes, A. W., & De Bruin, M. L. (2015). Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3792
View
Nielen, J. T., Emans, P. J., Dagnelie, P. C., Boonen, A., Lalmohamed, A., de Boer, A., et al. (2016). Severity of Diabetes Mellitus and Total Hip or Knee Replacement: A Population-Based Case-Control Study. Medicine (Baltimore). http://doi.org/10.1097/md.0000000000003739
View
Boef, A. G., Souverein, P. C., Vandenbroucke, J. P., Vlieg, van H., de Boer, A., le Cessie, S., & Dekkers, O. M. (2016). Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3956
View
Mahmoudpour, S. H., Baranova, E. V., Souverein, P. C., Asselbergs, F. W., de Boer, A., & van der Zee, A. H. M. -. (2016). Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.13090
View
Verhaegh, B. P., de Vries, F., Masclee, A. A., Keshavarzian, A., de Boer, A., Souverein, P. C., et al. (2016). High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. http://doi.org/10.1111/apt.13583
View
Gieling, E. M., van den Ham, H. A., van Onzenoort, H., Bos, J., Kramers, C., de Boer, A., et al. (2017). Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.13265
View
Stolk, L. M., de Vries, F., Ebbelaar, C., de Boer, A., Schalekamp, T., Souverein, P., et al. (2017). Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.13264
View
Bronsveld, H. K., Peeters, P., de Groot, M. C. H., de Boer, A., Schmidt, M. K., & De Bruin, M. L. (2017). Trends in breast cancer incidence among women with type-2 diabetes in British general practice. Prim Care Diabetes. http://doi.org/10.1016/j.pcd.2017.02.001
View